相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synthesis of Novel Pyrido[4,3-e][1,2,4]triazino[3,2-c][1,2,4] thiadiazine 6,6-dioxide Derivatives with Potential Anticancer Activity
Jaroslaw Slawinski et al.
MOLECULES (2016)
Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111
Carrie L. Lomelino et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents
Hany S. Ibrahim et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, Synthesis and In Vitro Antiproliferative Activity of Novel Isatin-Quinazoline Hybrids
Mohamed Fares et al.
ARCHIV DER PHARMAZIE (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Designing carbonic anhydrase inhibitors for the treatment of breast cancer
Claudiu T. Supuran et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Christopher A. Lipinski et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Sorafenib in liver cancer
Hyun Young Woo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Synthesis and Anticancer Activity of Isatin-Based Pyrazolines and Thiazolidines Conjugates
Dmytro Havrylyuk et al.
ARCHIV DER PHARMAZIE (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer
Eng-Huat Tan et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
1,3-Dipolar Cycloaddition of Hydrazones with α-Oxo-ketenes: A Three-Component Stereoselective Entry to Pyrazolidinones and an Original Class of Spirooxindoles
Marc Presset et al.
ORGANIC LETTERS (2011)
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
K. L. Vine et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Cheryl A. London et al.
CLINICAL CANCER RESEARCH (2009)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416
Bulbul Pandit et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Small molecule inhibitors of protein kinases in cancer - How to overcome resistance
R. Griffith et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2006)
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate
H Prenen et al.
CLINICAL CANCER RESEARCH (2006)
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing
C Sessa et al.
EUROPEAN JOURNAL OF CANCER (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells
K Spiekermann et al.
EXPERIMENTAL HEMATOLOGY (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
分享论文
